Table 5 Top 20 pfsSNVs enriched in patients with specific cancer type (full list in Supplementary Table 5).
PfsSNVs | Cancer Type | PfsSNVs Associated Sample | Total Sample | P-Value |
|---|---|---|---|---|
[G]2PIK3CA-E545K-Phosphorylation | DOID:1612/breast cancer | 63 | 973 | 9.62E-85 |
[L]NRAS-Q61R-Binding Site | DOID:4159/skin cancer | 44 | 370 | 9.94E-51 |
[G]PIK3CA-E542K-Phosphorylation | DOID:1612/breast cancer | 41 | 973 | 4.43E-48 |
[G]CDC27-A274D-Phosphorylation | DOID:1793/pancreatic cancer | 44 | 210 | 1.59E-41 |
[G]PIK3CA-E545K-Phosphorylation | DOID:4362/cervical cancer | 33 | 198 | 5.25E-36 |
[G]KRTAP4-L161V-Phosphorylation | DOID:1793/pancreatic cancer | 39 | 210 | 7.70E-35 |
[L]NRAS-Q61K-Binding Site | DOID:4159/skin cancer | 33 | 370 | 2.91E-34 |
[G]ANKRD36-T998S-Phosphorylation | DOID:1793/pancreatic cancer | 37 | 210 | 2.94E-32 |
[G]EVPL-R336S-Phosphorylation | DOID:1793/pancreatic cancer | 36 | 210 | 5.47E-31 |
[G]PIK3CA-E545K-Phosphorylation | DOID:11934/head and neck cancer | 28 | 508 | 1.92E-29 |
[L]PTEN-R130G-Active Site | DOID:363/uterine cancer | 28 | 305 | 4.59E-29 |
[G]NCOR1-Y20S-Phosphorylation | DOID:1793/pancreatic cancer | 34 | 210 | 1.72E-28 |
[L]TP53-R273C-Binding Site | DOID:1319/brain cancer | 31 | 287 | 8.97E-27 |
[L]NRAS-Q61R-Binding Site | DOID:1781/thyroid cancer | 27 | 390 | 3.68E-26 |
[G]UPF3A-V70L-Phosphorylation | DOID:1793/pancreatic cancer | 31 | 210 | 7.35E-25 |
[G]KRT8-R23C-Phosphorylation | DOID:1793/pancreatic cancer | 29 | 210 | 1.61E-22 |
[L]MEF2A-Y105C-Phosphorylation | DOID:1793/pancreatic cancer | 27 | 210 | 3.02E-20 |
[G]ZNF814-A337V-Phosphorylation | DOID:1793/pancreatic cancer | 27 | 210 | 3.02E-20 |
[G]SALL1-S159G-Phosphorylation | DOID:1793/pancreatic cancer | 26 | 210 | 3.88E-19 |
